Integrated biomarker approaches that consider multiple factors, such as leukocytosis, TILs, PD-L1 expression, TMB, and immune gene expression profiles, have the potential to improve patient outcomes by tailoring treatments to individual characteristics [25-30,33-36]. The gene discussed is CD274; the disease is Increased total leukocyte count.